← Leaderboards
Ronald J Buckanovich
Magee-Women'S Res Inst And Foundation
$14,686,030
Attributed
$19,017,855
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,597,355 · 15
By mechanism
R01$12,146,889 · 7
P50$8,520,545 · 3
DP2$2,317,500 · 1
U01$2,289,174 · 1
P30$235,081 · 2
T32$88,166 · 1
Top collaborators
- Lan Coffman5 shared
- Toren Finkel5 shared
- Anda M Vlad5 shared
- Euisik Yoon4 shared
- Robert Page Edwards3 shared
- Scott D Larsen3 shared
- Sandra Cascio2 shared
Most similar at Magee-Women'S Res Inst And Foundation
Same institution · by research overlap
- Sandra Cascio$1,600,259
- Anda M Vlad$2,135,923
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Robert C Bast · University Of Texas Md Anderson Can Ctr$22,987,143
Research focus
Malignant Neoplasm Of OvaryIn VivoCellsMalignant NeoplasmsIn VitroCancer CellTumorResponseTherapeutic TargetMediatingMolecularSignal TransductionStem CellsWomanTherapy ResistantResistanceCancer PatientNovel TherapeuticsPhenotypeReportingImmuneNeoplastic CellDiagnosisMortality
Grant awards (53)
HCC Ovarian Cancer SPORE$2,250,657
P50 · FY2025 · CA · contact PI
Defining the impact of stromal aging on ovarian cancer initiation$448,951
U01 · FY2025 · AG
Evaluating unique aspects of quiescent ovarian cancer cell biology for therapeutic targets$435,361
R01 · FY2025 · CA · contact PI
Project 3: Hedgehog Inhibition to Enhance Response to ICI Therapy$354,574
P50 · FY2025 · CA · contact PI
Administrative Core$223,870
P50 · FY2025 · CA · contact PI
Cancer Biology Program$42,676
P30 · FY2025 · CA · contact PI
HCC Ovarian Cancer SPORE$2,165,016
P50 · FY2024 · CA · contact PI
Defining the impact of stromal aging on ovarian cancer initiation$458,112
U01 · FY2024 · AG
Project 3: Hedgehog Inhibition to Enhance Response to ICI Therapy$447,715
P50 · FY2024 · CA · contact PI
Evaluating unique aspects of quiescent ovarian cancer cell biology for therapeutic targets$413,594
R01 · FY2024 · CA · contact PI
ALDH Inhibition as Modulator of Tumor Immunobiology$408,231
R01 · FY2024 · CA · contact PI
Administrative Core$307,957
P50 · FY2024 · CA · contact PI
Cancer Biology Program$39,496
P30 · FY2024 · CA · contact PI
HCC Ovarian Cancer SPORE$2,163,827
P50 · FY2023 · CA · contact PI
Defining the impact of stromal aging on ovarian cancer initiation$458,112
U01 · FY2023 · AG
Evaluating unique aspects of quiescent ovarian cancer cell biology for therapeutic targets$438,083
R01 · FY2023 · CA · contact PI
ALDH Inhibition as Modulator of Tumor Immunobiology$427,724
R01 · FY2023 · CA · contact PI
Project 3: Hedgehog Inhibition to Enhance Response to ICI Therapy$372,036
P50 · FY2023 · CA · contact PI
The Function of EGFL6 in Ovarian Cancer Cell Biology, Tumor Initiation, and Therapy$336,667
R01 · FY2023 · CA · contact PI
Administrative Core$234,893
P50 · FY2023 · CA · contact PI
Cancer Biology Program$39,496
P30 · FY2023 · CA · contact PI
Defining the impact of stromal aging on ovarian cancer initiation$457,624
U01 · FY2022 · AG
ALDH Inhibition as Modulator of Tumor Immunobiology$431,843
R01 · FY2022 · CA · contact PI
The Function of EGFL6 in Ovarian Cancer Cell Biology, Tumor Initiation, and Therapy$336,667
R01 · FY2022 · CA · contact PI
Cancer Biology Program$39,496
P30 · FY2022 · CA · contact PI
ALDH Inhibition as Modulator of Tumor Immunobiology$14,478
R01 · FY2022 · CA · contact PI
Defining the impact of stromal aging on ovarian cancer initiation$466,375
U01 · FY2021 · AG
ALDH Inhibition as Modulator of Tumor Immunobiology$437,359
R01 · FY2021 · CA · contact PI
The Function of EGFL6 in Ovarian Cancer Cell Biology, Tumor Initiation, and Therapy$343,538
R01 · FY2021 · CA · contact PI
ALDH Inhibition as Modulator of Tumor Immunobiology$60,414
R01 · FY2021 · CA · contact PI
Cancer Biology Program$35,042
P30 · FY2021 · CA · contact PI
ALDH Inhibition as Modulator of Tumor Immunobiology$468,896
R01 · FY2020 · CA · contact PI
Using Microfluidic Single Cell Culture to Characterize Cancer Cell Asymmetric Division$357,769
R01 · FY2020 · CA · contact PI
The Function of EGFL6 in Ovarian Cancer Cell Biology, Tumor Initiation, and Therapy$349,525
R01 · FY2020 · CA · contact PI
Developing a Human in Mouse Cancer Model with a Completely Humanized Stroma$79,960
R01 · FY2020 · CA · contact PI
Cancer Biology Program$38,875
P30 · FY2020 · CA · contact PI
Developing a Human in Mouse Cancer Model with a Completely Humanized Stroma$583,011
R01 · FY2019 · CA · contact PI
Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy$572,426
R01 · FY2019 · CA
The Function of EGFL6 in Ovarian Cancer Cell Biology, Tumor Initiation, and Therapy$369,300
R01 · FY2019 · CA · contact PI
Using Microfluidic Single Cell Culture to Characterize Cancer Cell Asymmetric Division$347,262
R01 · FY2019 · CA · contact PI
Training in Cancer Therapeutics Research$88,166
T32 · FY2019 · CA · contact PI
Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy$603,477
R01 · FY2018 · CA
Developing a Human in Mouse Cancer Model with a Completely Humanized Stroma$593,295
R01 · FY2018 · CA · contact PI
Using Microfluidic Single Cell Culture to Characterize Cancer Cell Asymmetric Division$412,307
R01 · FY2018 · CA · contact PI
Developing a Human in Mouse Cancer Model with a Completely Humanized Stroma$681,408
R01 · FY2017 · CA · contact PI
Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy$636,181
R01 · FY2017 · CA
Using microfluidic single cell culture to characterize cancer cell asymmetric division$433,051
R01 · FY2017 · CA · contact PI
Targeting Ovarian Tumor Associated Myeloid Cells with Nanoparticles Therapeutics$322,663
R01 · FY2016 · CA · contact PI
Targeting Ovarian Tumor Associated Myeloid Cells with Nanoparticles Therapeutics$322,663
R01 · FY2015 · CA · contact PI
Targeting Ovarian Tumor Associated Myeloid Cells with Nanoparticles Therapeutics$312,983
R01 · FY2014 · CA · contact PI
Targeting Ovarian Tumor Associated Myeloid Cells with Nanoparticles Therapeutics$303,303
R01 · FY2013 · CA · contact PI
Targeting Ovarian Tumor Associated Myeloid Cells with Nanoparticles Therapeutics$313,450
R01 · FY2012 · CA · contact PI
Using embryonic stem cells to re-create a human tumor microenvironment to develop$2,317,500
DP2 · FY2008 · OD · contact PI